Axovant Sciences: A Buy At A Bargain Price
Seeking Alpha,
SummaryAxovant Sciences on Sept. 26, 2017, that its phase 3 MINDSET trial failed to meet the primary end points.
SummaryAxovant Sciences on Sept. 26, 2017, that its phase 3 MINDSET trial failed to meet the primary end points.
30 Sep 2016 Topline data from one of three ongoing Phase 3 trials for idalopirdine indicate that patients with mild to moderate…
Despite already extremely high valuations, the incredible run-up in biotech stocks continues. The Nasdaq Biotech Index is up 20…